About IRLAB Therapeutics

Company Description

Rooted in Nobel Prize-winning research, IRLAB has grown rapidly to become recognized and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders and especially Parkinson’s disease. We have a well-defined, strategically focused R&D pipeline of powerful new treatments targeting the various stages of Parkinson’s as they worsen over time throughout the patient’s journey of neurodegeneration.

Having a full range of effective disease management options for Parkinson’s patients is regarded as essential by both the medical and patient communities – and at the same time potentially a blockbuster pharmaceutical business.

Year founded



Arvid Wallgrens backe 20, 41346 Göteborg – Sweden

Shareholder information

Shares outstanding



Jan. 1, 2000

Stock exchange(s)

Nasdaq Stockholm



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.